Gan & Lee Pharmaceuticals. (603087.SS) SHH
Currency In CNY
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In CNY
Address
No. 8, Nanfeng West 1st Street
Beijing, BE 101109
China
Phone
86 10 8059 3699
Website
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
5309
First IPO Date
June 29, 2020
| Name | Title | Pay | Year Born |
| Kai Du | Deputy GM & Director | 0 | 1977 |
| Qianming Wang | Chief Financial Officer & Deputy GM | 0 | N/A |
| Li Zhou | Head of Accounting | 0 | N/A |
| Wei Chen | Chairman & GM | 0 | 1980 |
| Rong Zou | Deputy GM & Secretary | 0 | 1983 |
| Yajuan Feng | Head of Administrative Department | 0 | 1992 |
| Weiqiang Song | Deputy GM & Director | 0 | 1982 |
| Cheng Xing | Deputy General Manager | 0 | 1991 |
| Zifei Yuan | Deputy General Manager | 0 | 1989 |
| Ting Jia | Chief Medical Officer | 0 | N/A |
| Zhongru Gan | Founder & Chairman | 0 | 1948 |
| Zhi Li | Deputy General Manager | 0 | 1993 |
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.